Classification of Glioblastoma Based on Immunohistochemical Expression of IDH-1, p53, and ATRX: A Study from a Tertiary Care Center in South India

Abstract

Introduction

Glioblastoma (GBM) is the most common malignant brain tumor in adults characterized by an extremely aggressive clinical phenotype. Understanding the molecular markers involved in GBM is critical for development of more effective and targeted therapies. The present study attempts to study the prevalence of immunohistochemical expression of IDH-1, p53, and ATRX in GBMs in our population.

Materials and Methods

The present study is a descriptive cross-sectional study conducted in the department of pathology, on a total of 95 cases of GBM during the study period of 5 years. The immunohistochemical testing was done and evaluated.

Results

Out of 95 cases of GBM, 74 were IDH wild-type (IDH-1 − ) and 21 were IDH mutant (IDH-1 + ). In our study, 37.9% of cases showed p53 overexpression (p53 + ) and 46.3% of cases showed loss of ATRX expression (ATRX − ). A statistically significant association was found in the expression of p53 and ATRX among IDH mutant cases on combined three-protein analysis (p-value = 0.01). Majority of them were p53 negative (p53 − ) and showed ATRX loss. Among IDH wild-type cases, majority were negative for p53 with retained ATRX expression (ATRX + ), which was in concordance with other studies.

Conclusion

These findings suggest that the identification of combinations of these protein markers may be useful for the classification and thus it may help to provide a deeper understanding of the molecular heterogeneity and aggressiveness of GBM and may help in the development of targeted therapies.

Keywords

ATRX - glioblastoma - IDH-1 - immunohistochemistry - p53

Ethical Approval Statement

Ethical approval was obtained from the Institutional Ethics Committee prior to the initiation of the study.

Publication History

Article published online:
19 August 2025

• References

• 1 Chaurasia A, Park SH, Seo JW, Park CK. Immunohistochemical analysis of ATRX, IDH1, and p53 in glioblastoma and their correlations with patient survival. J Korean Med Sci 2016; 31 (08) 1208-1214
• 2 Lee KS, Choe G, Nam KH. et al. Immunohistochemical classification of primary and secondary glioblastomas. Korean J Pathol 2013; 47 (06) 541-548
• 3 Urbańska K, Sokołowska J, Szmidt M, Sysa P. Glioblastoma multiforme - an overview. Contemp Oncol (Pozn) 2014; 18 (05) 307-312
• 4 Dahuja G, Gupta A, Jindal A, Jain G, Sharma S, Kumar A. Clinicopathological correlation of glioma patients with respect to immunohistochemistry markers: a prospective study of 115 patients in a tertiary care hospital in North India. Asian J Neurosurg 2021; 16 (04) 732-737
• 5 Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170 (05) 1445-1453
• 6 Sharma S, Mathur K, Mittal A, Meel M, Jindal A, Kumar M. Study of surrogate immunohistochemical markers IDH-1, ATRX, BRAF V600E and p53 mutation in astrocytic and oligodendroglial tumors. Indian J Neurosurg 2023; 12 (02) 137-146
• 7 Haase S, Garcia-Fabiani MB, Carney S. et al. Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin Ther Targets 2018; 22 (07) 599-613
• 8 Forte IM, Indovina P, Iannuzzi CA. et al. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int J Oncol 2019; 54 (06) 2189-2199
• 9 Gülten G, Yalçın N, Baltalarlı B, Doğu G, Acar F, Doğruel Y. The importance of IDH1, ATRX and WT-1 mutations in glioblastoma. Pol J Pathol 2020; 71 (02) 127-137
• 10 Reuss DE, Sahm F, Schrimpf D. et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015; 129 (01) 133-146
• 11 Liu XY, Gerges N, Korshunov A. et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012; 124 (05) 615-625
• 12 Cai J, Zhang C, Zhang W. et al. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience 2016; 3 (7-8): 258-265
• 13 Stoyanov GS, Lyutfi E, Georgieva R. et al. Reclassification of glioblastoma multiforme according to the 2021 World Health Organization classification of central nervous system tumors: a single institution report and practical significance. Cureus 2022; 14 (02) e21822
• 14 Louise DN, Ohgaki H, Wiertz OD. et al. WHO Classification of Tumours of the Central Nervous System. Revised 4th ed.. Lyon: International Agency for Research on Cancer (IARC); 2016
• 15 Cantero D, Mollejo M, Sepúlveda JM. et al. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. Neurooncol Adv 2020; 2 (01) vdz059